Targeted Oncology
Articles by Targeted Oncology
Experts in the management of diffuse large B-cell lymphoma (DLBCL) discuss the use of novel CD19-antibody mono- and combination therapies to treat relapsed/refractory subpopulations.
Case 3: Atezolizumab/Nab-Paclitaxel for Triple Negative Breast Cancer
Published: | Updated:
Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast Cancer
Published: | Updated:
Case 3: Treatment After Progression in Triple-Negative Breast Cancer
Published: | Updated:
Case 3: The Use of Combination Therapy in Triple-Negative Breast Cancer
Published: | Updated:
Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
Published: | Updated:
Case 2: CDK4/6 Inhibitor Recommendations in ER+ Breast Cancer
Published: | Updated:
Case 2: Defining Strongly Versus Less Strongly ER+ Breast Cancer
Published: | Updated:
Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer
Published: | Updated:
